Zenas BioPharma Announces Board and Executive Changes

Ticker: ZBIO · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1953926

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

TL;DR

Zenas BioPharma shakes up board and exec comp on 6/10.

AI Summary

Zenas BioPharma, Inc. announced on June 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. This report is filed under Item 5.02 of the 8-K form.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.

Key Players & Entities

FAQ

What specific items are being reported in this 8-K filing?

This 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as the submission of matters to a vote of security holders.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is June 10, 2025.

What is the full legal name of the registrant?

The exact name of the registrant as specified in its charter is Zenas BioPharma, Inc.

In which state was Zenas BioPharma, Inc. incorporated?

Zenas BioPharma, Inc. was incorporated in Delaware.

What is the company's principal executive office address?

The address of the principal executive offices is 852 Winter Street, Suite 250, Waltham, MA 02451.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Zenas BioPharma, Inc. (ZBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing